Head and neck carcinoma

Sydney-based Biotech Ceases Trading to Raise Capital

Trading in shares of a Sydney-based clinical-stage biotechnical company halted as it had to raise $80 million through stock sales. Immutep Ltd (IMMP) is a clinical-stage biotechnical company that specialises in developing novel Lymphocyte Activation Gene (LAG-3) Immunotherapy for cancer...
- Advertisement -spot_img

Latest News

- Advertisement -spot_img